Roles of Rho‑associated kinase in lung cancer (Review)
- Authors:
- Muhammad Asyaari Zakaria
- Nor Fadilah Rajab
- Eng Wee Chua
- Gayathri Thevi Selvarajah
- Siti Fathiah Masre
-
Affiliations: Biomedical Science Programme, Centre for Toxicology and Health Risk Studies, Faculty of Health Sciences, National University of Malaysia, 50300 Kuala Lumpur, Malaysia, Centre for Healthy Ageing and Wellness, Faculty of Health Sciences, National University of Malaysia, 50300 Kuala Lumpur, Malaysia, Faculty of Pharmacy, National University of Malaysia, 50300 Kuala Lumpur, Malaysia, Department of Veterinary Clinical Studies, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Malaysia - Published online on: December 24, 2020 https://doi.org/10.3892/ijo.2020.5164
- Pages: 185-198
This article is mentioned in:
Abstract
 |
 |
 |
|
Remen T, Pintos J, Abrahamowicz M and Siemiatycki J: Risk of lung cancer in relation to various metrics of smoking history: A case-control study in Montreal. BMC Cancer. 18:12752018. View Article : Google Scholar : PubMed/NCBI | |
|
Dela Cruz CS, Tanoue LT and Matthay RA: Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Perez-Moreno P, Brambilla E, Thomas R and Soria JC: Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clin Cancer Res. 18:2443–2451. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gandara DR, Hammerman PS, Sos ML, Lara PN Jr and Hirsch FR: Squamous cell lung cancer: From tumor genomics to cancer therapeutics. Clin Cancer Res. 21:2236–2243. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J and Vooijs M: Drug resistance in non-small cell lung cancer: A potential for NOTCH targeting? Front Oncol. 8:2672018. View Article : Google Scholar : PubMed/NCBI | |
|
Gentzler RD and Johnson ML: Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist. 20:299–306. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Baxevanos P and Mountzios G: Novel chemotherapy regimens for advanced lung cancer: Have we reached a plateau? Ann Transl Med. 6:1392018. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas A, Rajan A and Giaccone G: Tyrosine kinase inhibitors in lung cancer. Hematol Oncol Clin North Am. 26:589–605. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chung CH: EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan. Oncol Lett. 18:6090–6100. 2019.PubMed/NCBI | |
|
Peng Y, Chen Z, Chen Y, Li S, Jiang Y, Yang H, Wu C, You F, Zheng C, Zhu J, et al: ROCK isoforms differentially modulate cancer cell motility by mechanosensing the substrate stiffness. Acta Biomater. 88:86–101. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Masre SF, Rath N, Olson MF and Greenhalgh DA: ROCK2/rasHa co-operation induces malignant conversion via p53 loss, elevated NF-k B and tenascin C-associated rigidity, but p21 inhibits ROCK2/NF-KB-mediated progression. Oncogene. 36:2529–2542. 2017. View Article : Google Scholar | |
|
Zheng Y, Xiang L, Chen M and Xiang C: MicroRNA-130a inhibits the proliferation, migration and invasive ability of hepatocellular carcinoma cells by downregulating Rho-kinase 2. Mol Med Rep. 18:3077–3084. 2018.PubMed/NCBI | |
|
Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL and Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Zhang Y, Wang S and Shi W: Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro. Can J Physiol Pharmacol. 88:874–879. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu F, Zhang Z, Wu G, Li Z, Zhang R, Ren J and Nong L: Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. Med Oncol. 28:565–571. 2011. View Article : Google Scholar | |
|
Huo Z, Su Y, Dong Y, Zheng Y, Zhang Q, Duan Y and Wang G: Rho-kinase inhibition by Fasudil promotes tumor maturation and apoptosis in small-cell lung cancer. Am J Transl Res. 12:4354–4370. 2020.PubMed/NCBI | |
|
Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z and Huang JA: miR-335-5p inhibits TGF-|31-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res. 20:2252019. View Article : Google Scholar | |
|
Cui G, Cui M, Li Y, Liang Y, Li W, Guo H and Zhao S: MiR-186 targets ROCK1 to suppress the growth and metastasis of NSCLC cells. Tumor Biol. 35:8933–8937. 2014. View Article : Google Scholar | |
|
Hosono Y, Yamaguchi T, Mizutani E, Yanagisawa K, Arima C, Tomida S, Shimada Y, Hiraoka M, Kato S, Yokoi K, et al: MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J. 31:481–493. 2012. View Article : Google Scholar : | |
|
Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K and Narumiya S: ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 392:189–193. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatasu A and Kaibuchi K: Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15:2208–2216. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y and Kaibuchi K: Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 271:20246–20249. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, Obinata T, Ohashi K, Mizuno K and Narumiya S: Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 285:895–898. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S and Mizuno K: Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem. 275:3577–3582. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hoon JL, Tan MH and Koh CG: The regulation of cellular responses to mechanical cues by Rho GTPases. Cells. 5:172016. View Article : Google Scholar : | |
|
Julian L and Olson MF: Rho-associated coiled-coil containing kinases (ROCK), structure, regulation, and functions. Small GTPases. 5:e298462014. View Article : Google Scholar | |
|
Riento K and Ridley AJ: Rocks: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 4:446–456. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rath N and Olson MF: Rho-associated kinases in tumorigenesis: Re-considering ROCK inhibition for cancer therapy. EMBO Rep. 13:900–908. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Samuel MS, Lopez JI, McGhee EJ, Croft DR, Starchan D, Timpson P, Munro J, Schröder E, Zhou J, Brunton VG, et al: Actomyosin-mediated cellular tension drives increased tissue stiffness and ß-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell. 19:776–791. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chow W, Amaya CN, Rains S, Chow M, Dickerson EB and Bryan BA: Growth attenuation of cutaneous angiosarcoma with propranolol-mediated ß-blockade. JAMA Dermatol. 151:1226–1229. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N and Narumiya S: The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15:1885–1893. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kümper S, Mardakheh FK, McCarthy A, Yeo M, Stamp GW, Paul A, Worboys J, Sadok A, Jprgensen C, Guichard S and Marshall CJ: Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. Elife. 5:e129942016. View Article : Google Scholar : PubMed/NCBI | |
|
Chevrier V, Piel M, Collomb N, Saoudi Y, Frank R, Paintrand M, Narumiya S, Bornens M and Job D: The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol. 157:807–817. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Iizuka M, Kimura K, Wang S, Kato K, Amano M, Kaibuchi K and Mizoguchi A: Distinct distribution and localization of Rho-kinase in mouse epithelial, muscle and neural tissues. Cell Struct Funct. 37:155–175. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hu C, Zhou H, Liu Y, Huang J, Liu W, Zhang Q, Tang Q, Sheng F, Li G and Zhang R: ROCK1 promotes migration and invasion of non-small-cell lung cancer cells through the PTEN/PI3K/FAK pathway. Int J Oncol. 55:833–844. 2019.PubMed/NCBI | |
|
Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H and Duan Z: ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 29:1259–1266. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vieira GM, Roberto GM, Lira RC, Engel EE, Tone LG and Brassesco MS: Prognostic value and functional role of ROCK2 in pediatric Ewing sarcoma. Oncol Lett. 15:2296–2304. 2018.PubMed/NCBI | |
|
Zakaria MA, Rajab NF, Chua EW, Selvarajah GT and Masre SF: The roles of tissue rigidity and its underlying mechanisms in promoting tumor growth. Cancer Invest. 38:445–462. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Amaya CN, Mitchell DC and Bryan BA: Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth. BMC Cancer. 17:4852017. View Article : Google Scholar : PubMed/NCBI | |
|
Masre SF, Rath N, Olson MF and Greenhalgh DA: Epidermal ROCK2-induces AKT1/GSK3ß/ß-catenin, NFkB and dermal tenascin-C; but enhanced differentiation and p53/p21 inhibit papilloma. Carcinogenesis. 41:1409–1420. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Bharadwaj SS, Guzman G, Vishnubhotla R and Glover SC: ROCK I has more accurate prognostic value than met in predicting patient survival in colorectal cancer. Anticancer Res. 35:3267–3273. 2015.PubMed/NCBI | |
|
Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, et al: The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 149:642–655. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X and Liu M: Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 7:113632016. View Article : Google Scholar : PubMed/NCBI | |
|
Kang CG, Im E, Lee HJ and Lee EO: Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice. Bioorg Med Chem Lett. 27:1914–1918. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yan SH, Gao HC, Meng HY, Cheng L, Zhe L, Cao GS, Yan WQ and Xin H: Role of Rock 1 protein in non-small cell lung cancer. Biomed Res. 28:2530–2534. 2017. | |
|
Zhang C, Qin S, Qin L, Liu L, Sun W, Li X, Li N, Wu R and Wang X: Cigarette smoke extract-induced p120-mediated NF-kB activation in human epithelial cells is dependent on the RhoA/ROCK pathway. Sci Rep. 6:231312016. View Article : Google Scholar | |
|
Duong-Quy S, Dao P, Hua-Huy T, Guilluy C, Pacaud P and Dinh-Xuan AT: Increased Rho-kinase expression and activity and pulmonary endothelial dysfunction in smokers with normal lung function. Eur Respir J. 37:349–355. 2011. View Article : Google Scholar | |
|
Tan X and Chen M: MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data. Tumor Biol. 35:12189–12200. 2014. View Article : Google Scholar | |
|
Zhang D, Zhang JY, Dai SD, Liu SL, Liu Y, Tang N and Wang EH: Co-expression of delta-catenin and RhoA is significantly associated with a malignant lung cancer phenotype. Int J Clin Exp Pathol. 7:3724–3732. 2014.PubMed/NCBI | |
|
Vishnubhotla R, Bharadwaj S, Sun S, Metlushko V and Glover SC: Treatment with Y-27632, a ROCK inhibitor, increases the proinvasive nature of SW620 cells on 3D collagen type 1 matrix. Int J Cell Biol. 2012:2591422012. View Article : Google Scholar : PubMed/NCBI | |
|
Samuel MS, Rath N, Masre SF, Boyle ST, Greenhalgh DA, Kochetkova M, Bryson S, Stevenson D and Olson MF: Tissue-selective expression of a conditionally-active ROCK2-estrogen receptor fusion protein. Genesis. 54:636–646. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Burgstaller G, Oehrle B, Gerckens M, White ES, Schiller HB and Eickelberg O: The instructive extracellular matrix of the lung: Basic composition and alterations in chronic lung disease. Eur Respir J. 50:16018052017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu S, Xu H, Wang W, Li S, Li H, Li T, Zhang W, Yu X and Liu L: The role of collagen in cancer: From bench to bedside. J Transl Med. 17:3092019. View Article : Google Scholar : PubMed/NCBI | |
|
Galbraith CG, Yamada KM and Sheetz MP: The relationship between force and focal complex development. J Cell Biol. 159:695–705. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wozniak MA, Desai R, Solski PA, Der CJ and Keely PJ: ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J Cell Biol. 163:583–595. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gkretsi V and Stylianopoulos T: Cell adhesion and matrix stiffness : Coordinating cancer cell invasion and metastasis. Front Oncol. 8:1452018. View Article : Google Scholar | |
|
Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, et al: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 12:1507–1514. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kataoka Y, Ohshio Y, Teramoto K, Igarashi T, Asai T and Hanaoka J: Hypoxia-induced galectin-3 enhances RhoA function to activate the motility of tumor cells in non-small cell lung cancer. Oncol Rep. 41:853–862. 2019. | |
|
Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D and Semenza GL: Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci USA. 111:E384–E393. 2014. View Article : Google Scholar | |
|
Rofstad EK, Gaustad JV, Egeland TA, Mathiesen B and Galappathi K: Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer. 127:1535–1546. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xue Y, Wu L, Liu Y, Ma Y, Zhang L, Ma X, Yang Y and Chen J: ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression. PLoS One. 10:e01200462015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Mei X, Wang L and Yang X: RhoA inhibits apoptosis and increases proliferation of cultured SPCA1 lung cancer cells. Mol Med Rep. 15:3963–3968. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Radziszewska A, Schroer SA, Choi D, Tajmir P, Radulovich N, Ho JC, Wang L, Liadis N, Hakem R, Tsao MS, et al: Absence of caspase-3 protects pancreatic p-cells from c-Myc-induced apoptosis without leading to tumor formation. J Biol Chem. 284:10947–10956. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu J and Shi W: The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother. 66:221–227. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xin T, Lv W, Liu D, Jing Y and Hu F: ROCK1 knockdown inhibits non-small-cell lung cancer progression by activating the LATS2-JNK signaling pathway. Aging (Albany NY). 12:12160–12174. 2020. View Article : Google Scholar | |
|
Chen W, Li Z, Bai L and Lin Y: NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed). 16:1172–1185. 2011. View Article : Google Scholar | |
|
Orgaz JL, Herraiz C and Sanz-Moreno V: Rho GTPases modulate malignant transformation of tumor cells. Small GTPases. 5:e290192014. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JH, Jang YS, Lee HJ, Lee CY, Shin DY and Oh SH: Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: Good and bad. Lab Anim Res. 35:302019. View Article : Google Scholar | |
|
Gu L, Wang Z, Zuo J, Li H and Zha L: Prognostic significance of NF-kB expression in non-small cell lung cancer: A meta-analysis. PLoS One. 13:e01982232018. View Article : Google Scholar | |
|
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, et al: Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 10(1 Suppl 1): S1–S63. 2015. View Article : Google Scholar : | |
|
Wang J, Sun L, Yang M, Luo W, Gao Y, Liu Z, Qiu X and Wang E: DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer. J Histochem Cytochem. 61:510–521. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xu N, Liu F, Wu S, Ye M, Ge H, Zhang M, Song Y, Tong L, Zhou J and Bai C: CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A. BMC Cancer. 20:2622020. View Article : Google Scholar : PubMed/NCBI | |
|
Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG and Lowry DR: E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: Role of Rho GTPases. Oncogene. 29:2760–2771. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Croft DR and Olson MF: The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. 26:4612–4627. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Street CA and Bryan BA: Rho kinase proteins-pleiotropic modulators of cell survival and apoptosis. Anticancer Res. 31:3645–3657. 2011.PubMed/NCBI | |
|
Tang Y, Hu C, Yang H, Cao L, Li Y, Deng P and Huang L: Rnd3 regulates lung cancer cell proliferation through notch signaling. PLoS One. 9:e1118972014. View Article : Google Scholar : PubMed/NCBI | |
|
Amano M, Nakayama M and Kaibuchi K: Rho-Kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 67:545–554. 2010. View Article : Google Scholar | |
|
Kang CG, Lee HJ, Kim SH and Lee EO: Zerumbone suppresses osteopontin-induced cell invasion through inhibiting the FAK/AKT/ROCK pathway in human non-small cell lung cancer a549 cells. J Nat Prod. 79:156–160. 2016. View Article : Google Scholar | |
|
Zhang Z, Ren JH, Li ZY, Nong L and Wu G: Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration. Oncol Rep. 27:1561–1566. 2012.PubMed/NCBI | |
|
Gandalovicova A, Vomastek T, Rosel D and Brabek J: Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget. 7:25022–25049. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Charras G and Paluch E: Blebs lead the way: How to migrate without lamellipodia. Nat Rev Mol cell Biol. 9:730–736. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mittal V: Epithelial mesenchymal transition in aggressive lung cancers. Adv Exp Med Biol. 890:37–56. 2016. View Article : Google Scholar | |
|
Lu X, Guo H, Chen X, Xiao J, Zou Y, Wang W and Chen Q: Effect of RhoC on the epithelial-mesenchymal transition process induced by TGF-ß1 in lung adenocarcinoma cells. Oncol Rep. 36:3105–3112. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Li X, Li X, Li X and Chen Z: LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting miR-484 in human lung cancer cells. J Cell Biochem. 119:4447–4457. 2018. View Article : Google Scholar | |
|
Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar | |
|
Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 9:267–285. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Song N, Ding Y, Yuan S, Li X, Cai H, Shi H and Luo Y: Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 69:7529–7537. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
El-Badrawy MK, Yousef AM, Shaalan D and Elsamanoudy AZ: Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity, pathologic type, and prognosis. J Bronchology Interv Pulmonol. 21:327–334. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, Görn M, Vohwinkel G, Edler L, Fiedler W and Hossfeld DK: Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 50:51–58. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chang YW, Bean RR and Jakobi R: Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression. Recent Pat Anticancer Drug Discov. 4:110–124. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC and Griffioen AW: Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 1806:18–28. 2010.PubMed/NCBI | |
|
Xia Y, Cai XY, Fan JQ, Zhang LL, Ren JH, Li ZY, Zhang RG, Zhu F and Wu G: The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms. Int J Cancer. 144:2227–2238. 2019. View Article : Google Scholar | |
|
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lontos K, Adamik J, Tsagianni A, Galson DL, Chirgwin JM and Suvannasankha A: The role of semaphorin 4D in bone remodeling and cancer metastasis. Front Endocrinol (Lausanne). 9:3222018. View Article : Google Scholar | |
|
Zahra FT, Sajib MS, Ichiyama Y, Akwii RG, Tullar PE, Cobos C, Minchew SA, Doci CL, Zheng Y, Kubota Y, et al: Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological in vivo angiogenesis. Sci Rep. 9:116662019. View Article : Google Scholar : PubMed/NCBI | |
|
Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, et al: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: Results of a prospective placebo-controlled double-blind trial. J Neurosurg. 76:571–577. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Liu Y, Zong Z and Tian D: The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother. 64:58–62. 2010. View Article : Google Scholar | |
|
Miyamoto C, Maehata Y, Motohashi K, Ozawa S, Ikoma T, Hidaka K, Wada-Takahashi S, Takahashi SS, Yoshino F, Yoshida A, et al: Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma. Biomed Res. 35:381–388. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Y, Cai XY, Fan JQ, Zhang LL, Ren JH, Chen J, Li ZY, Zhang RG, Zhu F and Wu G: Rho kinase inhibitor fasudil suppresses the vasculogenic mimicry of B16 mouse melanoma cells both in vitro and in vivo. Mol Cancer Ther. 14:1582–1590. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin SS, Li FF, Sun L, Fan W, Gu M, Zhang LY, Qin S and Yuan ST: Marsdenia tenacissima extract suppresses A549 cell migration through regulation of CCR5-CCL5 axis, Rho C, and phosphorylated FAK. Chin J Nat Med. 14:203–209. 2016.PubMed/NCBI | |
|
Kang CG, Han HJ, Lee HJ, Kim SH and Lee EO: Rho-associated kinase signaling is required for osteopontin-induced cell invasion through inactivating cofilin in human non-small cell lung cancer cell lines. Bioorganic Med Chem Lett. 25:1956–1960. 2015. View Article : Google Scholar | |
|
Umelo IA, Wever OD, Kronenberger P, Noor A, Teugels E, Chen G, Bracke M and Grève JD: Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells. Lung Cancer. 90:167–174. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, et al: LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget. 6:38469–38486. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai YM, Yang CJ, Hsu YL, Wu LY, Tsai YC, Hung JY, Lien CT, Huang MS and Kuo PL: Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/Rho signaling pathway. Integr Cancer Ther. 10:341–349. 2011. View Article : Google Scholar | |
|
Zhao H, Jiao Y and Zhang Z: Deguelin inhibits the migration and invasion of lung cancer A549 and H460 cells via regulating actin cytoskeleton rearrangement. Int J Clin Exp Pathol. 8:15582–15590. 2015. | |
|
Patlolla JM, Qian L, Biddick L, Zhang Y, Desai D, Amin S, Lightfoot S and Rao CV: ß-Escin inhibits NNK-induced lung adenocarcinoma and ALDH1A1 and RhoA/Rock expression in A/J mice and growth of H460 human lung cancer cells. Cancer Prev Res (Phila). 6:1140–1149. 2013. View Article : Google Scholar | |
|
Aung TN, Qu Z, Kortschak RD and Adelson DL: Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci. 18:6562017. View Article : Google Scholar : | |
|
Surien O, Ghazali AR and Masre SF: Lung cancers and the roles of natural compounds as potential chemotherapeutic and chemopreventive agents. Biomed Pharmacol J. 12:85–98. 2019. View Article : Google Scholar | |
|
Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors Stephen. Biochem J. 351:95–105. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Patel RA, Liu Y, Wang B, Li R and Sebti SM: Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene. 33:550–555. 2014. View Article : Google Scholar : | |
|
Zhang B, Pan X, Cobb GP and Anderson TA: MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar | |
|
Iqbal MA, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 70:3–20. 2019. View Article : Google Scholar | |
|
Ye Z, Yin S, Su Z, Bai M, Zhang H, Hei Z and Cai S: Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget. 7:37524–37535. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Mol Cell Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar | |
|
Wu C, Cao Y, He Z, He J, Hu C, Duan H and Jiang J: Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 232:85–95. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez-Hernandez I, Cantelli G, Bruce F and Sanz-Moreno V: Rho, ROCK and actomyosin contractility in metastasis as drug targets. F1000Res. 5:F1000 Faculty Rev-783. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Han L, Shan S, Sun Y and Mao Y: KRT14 promoting invasion and migration of lung cancer cells through ROCK-1 signaling pathway. Int J Clin Exp Pathol. 10:795–803. 2017. | |
|
Wu Y, Shen QW, Niu YX, Chen XY, Liu HW and Shen XY: LncNORAD interference inhibits tumor growth and lung cancer cell proliferation, invasion and migration by down-regulating CXCR4 to suppress RhoA/ROCK signaling pathway. Eur Rev Med Pharmacol Sci. 24:5446–5455. 2020.PubMed/NCBI | |
|
Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD and Han H: Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. PLoS One. 12:e01838712017. View Article : Google Scholar : PubMed/NCBI | |
|
Shin JY, Kim Y Il, Cho SJ, Lee MK, Kook MC, Lee JH, Lee SS, Ashktorab H, Smoot DT, Ryu KW, et al: MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PLoS One. 9:e852052014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Li G, Zhang Q, Tang Q, Huang J, Hu C, Liu Y, Wang Q, Liu W, Gao N and Zhou S: Hirsutine induces mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3 ß pathway in human lung cancer cells. Cell Death Dis. 9:5982018. View Article : Google Scholar | |
|
Lin L, Li M, Lin L, Xu X, Jiang G and Wu L: FPPS mediates TGF-ß1-induced non-small cell lung cancer cell invasion and the EMT process via the RhoA/Rock1 pathway. Biochem Biophys Res Commun. 496:536–541. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M and Narumiya S: Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 57:976–983. 2000.PubMed/NCBI | |
|
Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, et al: RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov. 3:444–457. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tomasini P, Walia P, Labbe C, Jao K and Leighl NB: Targeting the KRAS pathway in non-small cell lung cancer. Oncologist. 21:1450–1460. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Korpanty GJ, Graham DM, Vincent MD and Leighl NB: Biomarkers that currently effect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS. Front Oncol. 4:2042014. View Article : Google Scholar | |
|
Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA and Dimitroulakos J: Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation by targeting rho proteins. Oncogene. 29:4682–4692. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, et al: Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with egfr mutation. J Thorac Oncol. 10:910–923. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zitvogel L and Kroemer G: Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 1:1223–1225. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et al: Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Li G and Wang Y and Wang Y, Zhao S, Haihong P, Zhao H and Wang Y: PD-L1 Expression in lung cancer and its correlation with driver mutations: A meta-analysis. Sci Rep. 7:102552017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H and Chung JH: PD-L1 testing in non-small cell lung cancer: Past, present, and future. J Pathol Transl Med. 53:199–206. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cho WY, Hong SH, Singh B, Islam MA, Lee S, Lee AY, Gankhuyag N, Kim JE, Yu KN, Kim KH, et al: Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. Eur J Pharm Biopharm. 94:450–462. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J and Ma D: The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 9:3562018. View Article : Google Scholar : PubMed/NCBI | |
|
Nwosu ZC, Ebert MP, Dooley S and Meyer C: Caveolin-1 in the regulation of cell metabolism: A cancer perspective. Mol Cancer. 15:712016. View Article : Google Scholar : PubMed/NCBI | |
|
Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, Chan SK, Jones SJ, Leung SP, Masoudi H, et al: Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 68:8210–8220. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Arpaia E, Blaser H, Quintela-Fandino M, Duncan G, Leong HS, Ablack A, Nambiar SC, Lind EF, Silvester J, Fleming CK, et al: The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 31:884–896. 2012. View Article : Google Scholar : | |
|
Urra H, Torres VA, Ortiz RJ, Lobos L, Diaz MI, Diaz N, Härtel S, Leyton L and Quest AF: Caveolin-1-enhanced motility and focal adhesion turnover require Tyrosine-14 but not accumulation to the rear in metastatic cancer cells. PLoS One. 7:e330852012. View Article : Google Scholar : PubMed/NCBI | |
|
Reck M and Rabe KF: Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, et al: Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 139:60–67. 2020. View Article : Google Scholar : | |
|
Hanahan D: Rethinking the war on cancer. Lancet. 383:558–563. 2014. View Article : Google Scholar | |
|
Malone ER, Oliva M, Sabatini PJB, Stockley TL and Siu LL: Molecular profiling for precision cancer therapies. Genome Med. 12:82020. View Article : Google Scholar : PubMed/NCBI | |
|
Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, et al: Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One. 9:e864592014. View Article : Google Scholar : PubMed/NCBI |
